我們已在上線！ 進一步了解
DSGN圖示

Design Therapeutics
DSGN

10.31 USD
-0.17
1.62%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
10.31
0.00
0%
1天
-1.62%
5天
-11.65%
1個月
-17.59%
3個月
-18.24%
6個月
-17.59%
今年迄今
13.3%
1年
67.1%
5年
-24.41%
10年
-75.15%
 

關於： Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

員工： 55

醫療保健 生物科技

新聞

正面
中性
負面
市場情緒 3個月
正面 50%
中性 50%
負面 0%
正面
Seeking Alpha
12 天前
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]. The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements, but confirmation awaits 12-week results in Q1 2027. Upcoming catalysts include a registrational update in Q4 2026 for DT-216P2 FA and early-stage readouts for DM1 and FECD programs in 2027.
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
中性
GlobeNewsWire
上個月
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m.
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
正面
24/7 Wall Street
上個月
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
中性
GlobeNewsWire
2 個月前
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027  Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at quarter-end provide strong financial runway CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio.
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
中性
GlobeNewsWire
3 個月前
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1).
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
正面
Seeking Alpha
3 個月前
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible.
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
中性
GlobeNewsWire
4 個月前
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m.
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
正面
Benzinga
5 個月前
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
中性
Seeking Alpha
5 個月前
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
正面
Investors Business Daily
5 個月前
This Biotech Leader Ran Up As Much As 18% — And Then Lost It All
Design Therapeutics shares ran up early Monday on positive results in Friedreich's ataxia. And then, the biotech stock lost it all.
This Biotech Leader Ran Up As Much As 18% — And Then Lost It All
查看新聞排名
價格圖表採用Lightweight Charts™實作